A study presented at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago found an antibody-based experimental therapy is lengthening the life-span of patients suffering from ...
A Ministry of Health, Labor and Welfare research team has announced the five-year survival rates for people diagnosed with ...
MedPage Today on MSN
FDA OKs Perioperative Immunotherapy for Stomach Cancer
The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a chemotherapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback